Literature DB >> 2876074

Interaction of cyclosporin A with human lipoproteins.

D Sgoutas, W MacMahon, A Love, I Jerkunica.   

Abstract

The ultracentrifugal fractionation of human serum after previous incubation with cyclosporin A showed that, in healthy fasting individuals, 8% of cyclosporin A was found in the very low density lipoproteins (VLDL), 31% in the low density lipoproteins (LDL), 46% in the high density lipoproteins (HDL) and 15% in the non-lipoprotein protein fraction. In non-fasted, healthy and in non-fasted, lipaemic individuals, 7 and 6% of cyclosporin A was found in chylomicrons, 9 and 13% in VLDL, 28 and 30% in LDL, 39 and 37% in HDL, and 12 and 13% in the non-lipoprotein protein fraction, respectively. In patients receiving cyclosporin A the distribution varied from 12 to 19% in VLDL, 21 to 28% in LDL, 33 to 43% in HDL, and 13 to 20% in non-lipoprotein proteins. The interaction between cyclosporin A and isolated normal human lipoproteins was also studied by ultrafiltration. All lipoproteins exhibited a non-saturable, low affinity, high capacity uptake for cyclosporin A. Analysis of the uptake by phospholipid vesicles showed a similar uptake, suggesting that cyclosporin A dissolves in the lipophilic portion of the lipoprotein molecule rather than being associated with specific binding sites.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2876074     DOI: 10.1111/j.2042-7158.1986.tb03085.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  17 in total

Review 1.  Optimisation of immunosuppressive therapy using pharmacokinetic principles.

Authors:  J Grevel
Journal:  Clin Pharmacokinet       Date:  1992-11       Impact factor: 6.447

2.  Potentiation of vascular smooth muscle cell activity by cyclosporin A.

Authors:  R Locher; R Huss; W Vetter
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 3.  Clinically significant drug interactions with cyclosporin. An update.

Authors:  C Campana; M B Regazzi; I Buggia; M Molinaro
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

4.  Cyclosporine transfer from low- and high-density lipoproteins is partially influenced by lipid transfer protein I triglyceride transfer activity.

Authors:  K M Wasan; R Subramanian; J W Chou; M Ramaswamy; P H Pritchard
Journal:  Pharm Res       Date:  1999-07       Impact factor: 4.200

5.  Decreased cyclosporine exposure during the remission of nephrotic syndrome.

Authors:  Mara Medeiros; José Pérez-Urizar; Natalia Mejía-Gaviria; Eduardo Ramírez-López; Gilberto Castañeda-Hernández; Ricardo Muñoz
Journal:  Pediatr Nephrol       Date:  2006-10-20       Impact factor: 3.714

6.  Vascular effects of cyclosporine A in vivo and in vitro.

Authors:  G Ferns; M Reidy; R Ross
Journal:  Am J Pathol       Date:  1990-08       Impact factor: 4.307

Review 7.  Distribution of cyclosporin in organ transplant recipients.

Authors:  Fatemeh Akhlaghi; Andrew K Trull
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

8.  Ontogeny of plasma proteins, albumin and binding of diazepam, cyclosporine, and deltamethrin.

Authors:  Pankaj K Sethi; Catherine A White; Brian S Cummings; Ronald N Hines; Srinivasa Muralidhara; James V Bruckner
Journal:  Pediatr Res       Date:  2015-11-16       Impact factor: 3.756

9.  The distribution of o,p'-DDD (mitotane) among serum lipoproteins in normo- and hypertriglyceridemia.

Authors:  D O Gebhardt; A J Moolenaar; A P van Seters; E A van der Velde; J A Gevers Leuven
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

10.  External evaluation of population pharmacokinetic models for ciclosporin in adult renal transplant recipients.

Authors:  Jun-Jun Mao; Zheng Jiao; Hwi-Yeol Yun; Chen-Yan Zhao; Han-Chao Chen; Xiao-Yan Qiu; Ming-Kang Zhong
Journal:  Br J Clin Pharmacol       Date:  2017-11-03       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.